Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AGIO Agios Pharmaceuticals, Inc.

未开盘 04-30 16:00:00 EDT

28.00

-0.05

-0.18%

盘后28.00

+0.000.00%

19:06 EDT

最高28.68	最低27.71	成交量130.60万
今开28.07	昨收28.05	日振幅3.46%
总市值16.65亿	流通市值14.17亿	总股本5,947万
成交额3,669万	换手率2.58%	流通股本5,062万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals, Inc.","latestPrice":28,"timestamp":1777579200000,"preClose":28.05,"halted":0,"volume":1306003,"hourTrading":{"tag":"盘后","latestPrice":28,"preClose":28,"latestTime":"19:06 EDT","volume":47926,"amount":1341149.95,"timestamp":1777590416837,"change":0,"changeRate":0,"amplitude":0.015714},"delay":0,"changeRate":-0.0017825311942959254,"floatShares":50618600,"shares":59471609,"eps":-7.12035,"marketStatus":"未开盘","change":-0.05,"latestTime":"04-30 16:00:00 EDT","open":28.07,"high":28.68,"low":27.71,"amount":36692898.706709996,"amplitude":0.034581,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.12035,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777622400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":28.05,"preHourTrading":{"tag":"盘前","latestPrice":27.01,"preClose":28.05,"latestTime":"09:01 EDT","volume":946,"amount":25544.01025,"timestamp":1777554073610,"change":-1.04,"changeRate":-0.037077,"amplitude":0.052406},"postHourTrading":{"tag":"盘后","latestPrice":28,"preClose":28,"latestTime":"19:06 EDT","volume":47926,"amount":1341149.95,"timestamp":1777590416837,"change":0,"changeRate":0,"amplitude":0.015714},"volumeRatio":0.965543,"impliedVol":0.489,"impliedVolPercentile":0.1633},"requestUrl":"/m/hq/s/AGIO","defaultTab":"news","newsList":[{"id":"1119640323","title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增41.55%，关注mitapivat加速审批进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119640323","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119640323?lang=zh_cn&edition=full","pubTime":"2026-04-23 03:29","pubTimestamp":1776886159,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.将于2026年04月29日盘前发布最新季度财报，市场关注营收增速与研发催化的兑现节奏。收入构成显示，公司目前以“产品”作为主要收入来源，上季度该口径金额为5,402.80万美元，收入集中度较高。主要依据包括：对本季度营收同比增长41.55%的共识预期、调整后每股收益同比变动收窄至-0.95%、以及公司已就mitapivat在镰状细胞病适应症的加速批准路径与监管方进行沟通并推进补充申请准备。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增41.55%，关注mitapivat加速审批进展","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126759159","title":"诺和诺德公布镰状细胞病药物后期数据 竞争对手Agios制药盘前重挫15.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126759159","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126759159?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:36","pubTimestamp":1776688619,"startTime":"0","endTime":"0","summary":"在竞争对手诺和诺德公布其镰状细胞病药物的后期临床试验数据后，Agios制药公司股价在盘前交易中暴跌15.5%。这一大幅下跌反映出市场对Agios核心产品面临潜在竞争威胁的担忧。\n诺和诺德披露的积极临床数据可能重塑镰状细胞病治疗领域的竞争格局，直接冲击Agios制药在该领域的市场地位。投资者迅速做出反应，大幅抛售Agios股票，导致其股价急剧下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141173806","title":"Agios与FDA召开Pre-SNDA会议后 推进米塔匹韦在镰状细胞病领域获美国加速批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1141173806","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141173806?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:03","pubTimestamp":1774955001,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals（纳斯达克代码：AGIO）宣布，在与美国食品药品监督管理局（FDA）成功举行新药上市申请前（Pre-SNDA）会议后，公司正积极推进其候选药物米塔匹韦（mitapivat）用于治疗镰状细胞病（SCD）的加速批准进程。\n此次关键会议明确了米塔匹韦在美国寻求加速批准的可行路径，标志着该药物在解决这一严重血液疾病方面迈出了重要一步。公司计划基于现有临床数据，尽快向FDA提交上市申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116513298","title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增28.81%，机构观点偏审慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1116513298","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116513298?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:29","pubTimestamp":1770262141,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc.预计在2026年02月12日发布最新季度财报，市场关注本季度营收与盈利承压的平衡，以及管线商业化进展对现金流的改善趋势。市场一致预期本季度Agios Pharmaceuticals, Inc.营收约为1,201.37万美元，同比增长28.81%；调整后每股收益预计为-1.95美元，同比降幅15.17%；息税前利润预计为-1.28亿美元，同比降幅17.77%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Agios Pharmaceuticals, Inc.本季度营收预计增28.81%，机构观点偏审慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123073264","title":"Agios Pharmaceuticals：预计2026年上半年启动AG-181与苯丙酮尿症Ib期机制验证试验，下半年确认机制验证结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1123073264","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123073264?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:09","pubTimestamp":1768219791,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals宣布，公司计划于2026年上半年启动针对苯丙酮尿症（PKU）的药物AG-181的Ib期机制验证临床试验。该试验旨在深入评估AG-181的作用机制与疗效潜力。\n若试验进展顺利，Agios将在2026年下半年确认AG-181的机制验证结果，为后续临床开发提供关键数据支持。这一里程碑将有助于进一步明确该疗法在治疗苯丙酮尿症方面的科学依据与开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163094485","title":"Agios Pharmaceuticals, Inc. 公布2026年战略重点及关键里程碑，全力加速罕见病产品组合增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1163094485","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163094485?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:07","pubTimestamp":1768219641,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 已正式勾勒出直至2026年的战略蓝图，明确了核心优先事项与一系列关键发展节点。该公司旨在以此为核心驱动力，显著加快其罕见病治疗产品组合的扩展步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108459995","title":"Agios制药公司预计2026年第一季度召开Mitapivat治疗镰状细胞病的新药申请前会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1108459995","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108459995?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219482,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals Inc宣布，针对其在研药物Mitapivat治疗镰状细胞病的研发计划，预计将于2026年第一季度与美国食品药品监督管理局举行新药申请提交前的会议。Mitapivat作为一种口服的丙酮酸激酶激活剂，其在镰状细胞病这一遗传性血液疾病领域的开发进展备受市场关注。公司此举标志着该药物研发进入了重要的后期阶段，为后续正式提交上市申请奠定基础。市场将密切关注此次会议的结果，因其可能对Agios未来的产品管线布局和商业前景产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594955102","title":"高盛上调Agios(AGIO.US)目标价至28美元，看好地中海贫血新药Aqvesme上市前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2594955102","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594955102?lang=zh_cn&edition=full","pubTime":"2025-12-26 19:19","pubTimestamp":1766747977,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛把Agios Pharmaceuticals的12个月目标价从25美元上调至28美元，对应潜在涨幅约14%，维持“中性”评级。该行对Agios Pharmaceuticals的深度分析聚焦于其核心药物Aqvesme获FDA批准后的市场前景与风险评估。ENERGIZE-T方面，Aqvesme组10%的病人在48周内摆脱输血，安慰剂组只有1%，输血负荷下降幅度同样显著。综合来看，高盛认为Agios短期靠Aqvesme美国上市兑现第一波价值，中期看处方-收入错配何时收敛，长期则取决于镰状细胞病适应症能否再下一城。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594283351","title":"血液疾病药物获美国FDA批准扩大使用范围，Agios Pharmaceuticals股价飙涨近20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594283351","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594283351?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:35","pubTimestamp":1766622949,"startTime":"0","endTime":"0","summary":"12月25日，$美国食品$药品监督管理局批准了Agios Pharmaceuticals药物用于治疗某种血液疾病的扩大适应症，该股股价周三大幅上涨18.63%。地中海贫血是一种遗传性血液疾病，影响人体产生血红蛋白和健康红细胞的能力。在实施一项必需的安全计划后，Aqvesme预计将于下个月晚些时候上市。药品标签还将建议肝硬化患者不要使用。该药物已于2022年获得FDA批准，用于治疗成人丙酮酸激酶缺乏症所致的红细胞计数低下。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385732.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"血液疾病药物获美国FDA批准扩大使用范围，Agios Pharmaceuticals股价飙涨近20%","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142894347","title":"Agios Pharmaceuticals高管表示Aqvesme的年度费用约为每位患者425,000美元 - 财报电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1142894347","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142894347?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:28","pubTimestamp":1766582890,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals高管表示Aqvesme的引入费用大约为每位患者每年425,000美元 - 财报电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177135129","title":"Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%，因美国 FDA 批准其治疗血液疾病成人贫血的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1177135129","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177135129?lang=zh_cn&edition=full","pubTime":"2025-12-24 20:25","pubTimestamp":1766579112,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals, Inc. 股份在盘前上涨 9.8%，因美国 FDA 批准其治疗血液疾病成人贫血的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193620418","title":"美国FDA批准Agios的Aqvesme™（Mitapivat）用于治疗成人α或β地中海贫血引起的贫血","url":"https://stock-news.laohu8.com/highlight/detail?id=1193620418","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193620418?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:45","pubTimestamp":1766537109,"startTime":"0","endTime":"0","summary":"美国FDA批准Agios的Aqvesme™（Mitapivat）用于治疗成人α或β地中海贫血引起的贫血","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586231238","title":"Agios Pharmaceuticals, Inc.盘中异动 临近午盘大幅拉升5.08%报27.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586231238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586231238?lang=zh_cn&edition=full","pubTime":"2025-11-26 00:47","pubTimestamp":1764089237,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日00时47分，Agios Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.08%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Agios Pharmaceuticals, Inc.公司简介：Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司，旨在为罕见疾病开发差异化药物，其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126004717a7110a28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126004717a7110a28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584180017","title":"Agios Pharmaceuticals, Inc.股价重挫50.21% 市值跌6.63亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584180017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584180017?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:31","pubTimestamp":1763562687,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日22时31分，Agios Pharmaceuticals, Inc.股票出现波动，股价急速下跌50.21%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。其相关个股中，Kazia Therapeutics Limited、Biovie Inc C/Wts 08/08/2030、Fulcrum Therapeutics, Inc.涨幅较大，Kazia Therapeutics Limited、Clearmind Medicine Inc.、Can Fite Biopharma Ltd较为活跃，换手率分别为793.20%、68.35%、23.45%，振幅较大的相关个股有Bioatla, Inc.、Fulcrum Therapeutics, Inc.、冠科美博，振幅分别为9.84%、9.15%、8.04%。Agios Pharmaceuticals, Inc.公司简介：Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司，旨在为罕见疾病开发差异化药物，其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119223127a4ad1185&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119223127a4ad1185&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125155038","title":"Agios公司公布镰状细胞贫血症研究结果喜忧参半，引发对该药物未来前景担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1125155038","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125155038?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:17","pubTimestamp":1763558255,"startTime":"0","endTime":"0","summary":"11月19日，Agios Pharmaceuticals盘前跌近59%！周三公布了一项针对镰状细胞病的 3 期研究结果喜忧参半，这可能会降低其药物获得美国批准的希望。 在为期一年的研究中，接受 Agios 药物 Pyrukynd 治疗的患者中有 41% 的血红蛋白水平得到改善，而接受安慰剂治疗的参与者中只有 3% 的人达到了这一改善——这一结果具有统计学意义，并实现了两个主要研究目标之一。 ","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Agios公司公布镰状细胞贫血症研究结果喜忧参半，引发对该药物未来前景担忧","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140122793","title":"Agios Pharmaceuticals股价盘前下跌35.1%，因晚期镰状细胞药物试验未能实现主要目标之一","url":"https://stock-news.laohu8.com/highlight/detail?id=1140122793","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140122793?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:22","pubTimestamp":1763554935,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals股价盘前下跌35.1%，因晚期镰状细胞药物试验未能实现主要目标之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5d18614bb841112089a87d6203a0bc12","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168351762","title":"Agios：试验显示Mitapivat有利趋势，但在年度Scpcs发生率的主要终点上未达到统计显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1168351762","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168351762?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:02","pubTimestamp":1763553752,"startTime":"0","endTime":"0","summary":"Agios：试验显示Mitapivat有利趋势，但在年度Scpcs发生率的主要终点上未达到统计显著性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516630865","title":"Agios Pharmaceuticals, Inc.盘中异动 快速下挫5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516630865?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:45","pubTimestamp":1741013140,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时45分，Agios Pharmaceuticals, Inc.股票出现波动，股价急速下跌5.41%。Agios Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Agios Pharmaceuticals, Inc.公司简介：Agios Pharmaceuticals Inc 是一家专注于细胞代谢领域的生物制药公司，旨在为罕见疾病开发差异化药物，其研究重点是经典血液学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224541abe63813&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512207953","title":"Agios Pharmaceuticals, Inc.2024财年实现净利润6.74亿美元，同比增加291.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512207953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512207953?lang=zh_cn&edition=full","pubTime":"2025-02-17 00:01","pubTimestamp":1739721663,"startTime":"0","endTime":"0","summary":"2月17日，Agios Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为6.74亿美元，同比增加291.48%；其中营业收入为36.50百万美元，同比增加36.09%，每股基本收益为11.86美元。机构评级：截至2025年2月17日，当前有6家机构对Agios Pharmaceuticals, Inc.目标价做出预测，其中目标均价为56.67美元，其中最低目标价为45.00美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250217000114a2481c17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158994754","title":"Agios制药公司第四季度销售额1070万美元，高于预期的933万美元，净亏损9650万美元同比相比9590万美元，现金余额15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158994754","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158994754?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446968,"startTime":"0","endTime":"0","summary":"Agios制药公司发布了第四季度财报，报告显示销售额为1070万美元，高于预期的933万美元。公司的净亏损为9650万美元，而去年同期为9590万美元。此外，公司目前的现金余额为15亿美元。以上内容来自Benzinga Earnings专栏，原文如下：N","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":0.0878},{"period":"1month","weight":-0.1723},{"period":"3month","weight":0.0204},{"period":"6month","weight":-0.3525},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":0.0287}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agios Pharmaceuticals, Inc.于2007年8月7日在特拉华州注册成立。该公司是一家生物制药公司，致力于通过细胞代谢领域的领导地位改变患者的生活，目标是为罕见病创造差异化药物，重点是经典血液学。","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.538462,"avgChangeRate":-0.001595},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.007034},{"month":5,"riseRate":0.583333,"avgChangeRate":0.052252},{"month":6,"riseRate":0.666667,"avgChangeRate":0.045835},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals, Inc.","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Agios Pharmaceuticals, Inc.,AGIO,Agios Pharmaceuticals, Inc.股票,Agios Pharmaceuticals, Inc.股票老虎,Agios Pharmaceuticals, Inc.股票老虎国际,Agios Pharmaceuticals, Inc.行情,Agios Pharmaceuticals, Inc.股票行情,Agios Pharmaceuticals, Inc.股价,Agios Pharmaceuticals, Inc.股市,Agios Pharmaceuticals, Inc.股票价格,Agios Pharmaceuticals, Inc.股票交易,Agios Pharmaceuticals, Inc.股票购买,Agios Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals, Inc.(AGIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Agios Pharmaceuticals, Inc.(AGIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}